Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α

@article{Brunetti2016ImpairedBR,
  title={Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α},
  author={Giacomina Brunetti and Francesco Papadia and Albina Tummolo and Rira Fischetto and Francesca Nicastro and Laura Piacente and Aviva Ventura and Giorgio Mori and Angela Oranger and Isabella Gigante and Silvia Concetta Colucci and Maria Laura Ciccarelli and Maria Grano and L. Cavallo and Manuela Delvecchio and Maria Felicia Faienza},
  journal={Osteoporosis International},
  year={2016},
  volume={27},
  pages={2355-2365}
}
In this study, we investigated the bone cell activity in patients with osteogenesis imperfecta (OI) treated and untreated with neridronate. We demonstrated the key role of Dickkopf-1 (DKK1), receptor activator of nuclear factor-κB ligand (RANKL), and tumor necrosis factor alpha (TNF-α) in regulating bone cell of untreated and treated OI subjects. These cytokines could represent new pharmacological targets for OI. Bisphosphonates are widely used in the treatment of children with osteogenesis… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Similar Papers

Loading similar papers…